Beijing Children's Hospital Licenses Ultra-Sensitive MAP2K1 Mutation Detection Kit for LCH with 30 RMB per-Test Royalty

Recently, the State-owned Scientific and Technological Achievement Trading System released a public notice indicating that Beijing Children’s Hospital, Capital Medical University, intends to transfer its invention patent"Deep Targeted Sequencing for Detection of MAP2K1 Gene Mutations in Langerhans Cell Histiocytosis"Authorize the industry partner for commercialization. Both parties intend to proceed by way of an implementation license agreement, with“30 yuan sales commission per test”pricing agreement reached through such means. The patent is held byLi Zhigang, Cui Lei, Zhang Ruico-developed with others.

The core innovation of this patent lies in the integration ofPrecision Targeting, Ultra-Deep Sequencing, and Liquid BiopsyThree Major Technical Advantages: Specialized primers and detection systems were designed for two micro-hotspot regions of MAP2K1, the most critical driver gene in LCH, achieving for the first timeUltrasensitive monitoring of this gene mutation frequency in peripheral blood at a depth exceeding 100,000×. This enables the detection sensitivity to reach<0.1%, enabling the detection of minimal residual disease at levels undetectable by conventional methods, thereby providing early warning of recurrence risk before clinical symptoms manifest. These core advantages have elevated it from a laboratory technique to a key tool for dynamic clinical management and guiding personalized treatment.

In the field of rare pediatric diseases, the clinical management of Langerhans cell histiocytosis (LCH) has long faced a severe challenge:How to Achieve Effective and Human-Centric Disease Surveillance.This disease exhibits high heterogeneity; some pediatric patients face a risk of relapse after treatment, and its key driver genes—MAP2K1 Mutation Status, serve as “molecular signposts” for evaluating therapeutic efficacy and predicting disease progression.

However, traditional methods for obtaining this critical information rely on repeated invasive tissue biopsies or bone marrow aspirations. For pediatric patients, this not only entails physical pain and potential anesthesia risks but also makes it difficult for physicians to perform the necessary, high-frequency dynamic monitoring of disease status. In clinical practice, doctors often have to rely on lagging indicators, such as imaging findings, to assess disease progression—akin to navigating through fog—unable to capture the decisive “molecular signals” at the early stages of relapse or even during its nascent phase.

Behind this “difficulty in monitoring” lies a deeper technological bottleneck.

First,The Dilemma of Sensitivity:Even when tissue samples are obtained, the limited sensitivity of conventional genetic testing methods makes it difficult to detect trace amounts of residual tumor cells after treatment (minimal residual disease, MRD), yet these “sparks” are precisely the root cause of potential future recurrence.

Secondly,Lack of Tools:There is a lack of cost-effective, dedicated genetic testing tools for Langerhans cell histiocytosis (LCH) on the market; using large pan-cancer panels is akin to “using radar to find a needle,” resulting in high costs and insufficient specificity.

Finally,The Regret of Dynamic Management:Precision disease management requires continuous monitoring throughout the entire course of treatment, yet the limitations of invasive procedures make it difficult to implement this ideal “whole-course management” model.

The emergence of this patented technology directly addresses the three core pain points mentioned above. By designing specific primers targeting only two core hotspot regions of the MAP2K1 gene, and coupled with the construction of an ultra-deep sequencing system with a depth exceeding 100,000x, it achieves the detection of trace amounts of ctDNA (circulating tumor DNA) in blood.Ultra-high sensitivity detection (as low as below 0.1%), effectively equipping clinicians with a high-precision radar capable of detecting “molecular ripples.” It revolutionizes monitoring by enabling “liquid biopsy” using only a few milliliters of peripheral blood, transforming the pain of needle aspiration into the convenience of a simple blood draw. This makes safe, non-invasive, and repeatable dynamic monitoring of pediatric patients during treatment and recovery a reality, thereby advancing disease management to a truly meaningful level of“Personalized, Precise, and Comprehensive”A New Phase. This is not only a technological breakthrough but also a significant innovation in the clinical diagnosis and treatment model for rare pediatric diseases.

The commercialization value of this patent is rooted in its robust and cutting-edge technological innovations. Rather than a mere incremental improvement to existing sequencing technologies, it represents a multidimensional, systemic breakthrough tailored to the specific clinical monitoring scenarios of Langerhans Cell Histiocytosis (LCH), establishing a comprehensive capability that progresses from “detection” to “clear visualization” and ultimately to “early detection.”

Innovation Point 1: From “Broad Screening” to “Precise Targeting”: Designing Molecular “Probes” with Ultimate Specificity.Traditional pan-cancer panels cover a wide range of genes, but often fail to deliver satisfactory sequencing depth and cost-effectiveness for specific genes. The core innovation of this patent lies in “precision targeting.” By mining and analyzing extensive mutation data, researchers precisely identified two critical hotspots within the MAP2K1 gene, each less than 100 base pairs in length. For these small “bullseyes,” they designed and optimized two unique primer pairs. This approach is akin to equipping the monitoring task with two high-precision, high-sensitivity “exclusive keys,” ensuring that all sequencing resources are focused on the core targets, thereby achieving both efficiency and specificity from the outset.

Innovation 2: From “10,000×” to “100,000×” Coverage, Achieving Unprecedented Resolution in Ultra-Deep Sequencing.It is not enough to have only a precise “key”; a “magnifying glass” capable of detecting trace-level signals is also required. The crux of the patented technology lies in pushing sequencing depth to unprecedented levels.“100,000× (one hundred thousand-fold) or more”ultra-high levels. Such profound depth entails repetitive reading of each target locus, ensuring that mutant DNA fragments (ctDNA) present at trace levels in the blood—accounting for merely a few parts per ten thousand—are detected with high sensitivity. Rigorously validated, this technology achieves a limit of detection (LoD) as low as 0.06%, enabling it to sensitively capture “molecular signals” that are entirely overlooked by conventional methods, thereby providing a valuable time window for early warning of recurrence.

Innovation Point 3: From “Static Diagnosis” to “Dynamic Monitoring,” Pioneering a New Pathway for Full-Course Management with Liquid Biopsy.The most transformative innovation lies in the thorough reshaping of its application model. The patent specifies a “liquid biopsy” approach based on peripheral blood cfDNA, transforming the previous “single-time, static” genetic diagnosis that relied on invasive tissue samples into one that can be achieved through a simple blood draw.“Multiple, Dynamic”Monitoring. Clinical study data vividly demonstrate that, in some pediatric patients, imaging findings indicate signs of recurrenceA Few Months Ago, the frequency of MAP2K1 mutations in their blood has quietly increased. This elevates the technology beyond the scope of a mere detection tool, evolving it into a solution that spans the entire treatment continuum—pre-, intra-, and post-treatment."Risk Radar", truly achieving real-time monitoring and proactive intervention in disease states.

In summary, this patent, through ““Precise Target Design,” “Ultra-Deep Detection Capability,” and “Non-Invasive Dynamic Pathway”The integration of triple innovations has not only overcome the technical bottlenecks in monitoring minimal residual disease (MRD) in Langerhans cell histiocytosis (LCH), but also redefined the clinical paradigm for precision management of rare diseases.

The successful commercialization of this patent from Beijing Children’s Hospital is not an isolated case; rather, it is embedded within the broader context of rapid development and intense competition in global precision medicine, particularly in gene testing products and technologies for rare diseases. From laboratory innovation to market application, its value can be more clearly assessed only within the coordinate system of related domestic and international products and technologies.

In the field of genetic testing for Langerhans cell histiocytosis (LCH), international product and technological developments have primarily focused on enhancing the detection sensitivity and clinical utility of mutations in genes such as MAP2K1. For example, based onDroplet Digital PCR (ddPCR) TechnologyIt has been studied for the detection of MAP2K1 mutations in the plasma and urine of patients with Langerhans cell histiocytosis (LCH), with a theoretical detection sensitivity as low as 0.001% to 0.1%, thereby providing a highly sensitive tool option for non-invasive monitoring. Furthermore, studies have employedMultiplex PCR Combined with Next-Generation Sequencing (NGS)protocol successfully detected MAP2K1 mutations in formalin-fixed, paraffin-embedded (FFPE) LCH tissue samples, demonstrating the feasibility of applying high-depth sequencing to clinical specimens. The development trajectories of these technologies and products collectively point toward a clear objective:Achieving more precise and convenient molecular subtyping of diseases and monitoring of therapeutic efficacy.

In China, development in related fields has shown a parallel trend of building platform capabilities and innovating targeted solutions. On one hand, companies represented by BGI Genomics, their“DNBSEQ-T7” and other high-throughput sequencing platformsThis has provided a robust foundation of domestically developed tools for conducting high-depth targeted sequencing. On the other hand, clinical testing protocols for Langerhans Cell Histiocytosis (LCH) are still under continuous exploration. Domestic research teams have validated the feasibility of using high-depth targeted sequencing technology (sequencing depth >1000×) to detect gene mutations such as MAP2K1 and BRAF V600E in LCH tissue samples, laying the groundwork for their translation into clinically applicable products. However, there has previously been a market gap for mature diagnostic products specifically dedicated to LCH that feature the ultra-high sequencing depth (>100,000×) and ultra-high sensitivity (<0.1%) described in the aforementioned patents, and are designed for non-invasive dynamic monitoring via peripheral blood.

In summary, the commercial value of the patented technology undergoing transformation lies in its precise targeting of an underserved clinical niche. Globally, although high-sensitivity dPCR technologies and mature NGS platforms are available for related testing, integrating them into a singleStandardized, low-cost, and specifically designed for non-invasive dynamic monitoring of LCHa complete kit product, remains a gap in the market. In China, despite having powerful sequencing platforms and preliminary research foundations, there is also a lack of approved products directly targeting this scenario. The successful translation of this patent precisely combines cutting-edge sequencing strategies, innovative primer design, and clear clinical needs, filling the critical link from “general technology” to “specialized product.” Its implementation not only provides LCH patients with a superior monitoring tool but also explores a feasible path for developing internationally competitive “flagship products” in the field of precise diagnosis of rare diseases in our country.

* Patent transaction information is provided by CSTT